Latest News
-
Strong Listing: Vodafone Idea FPO Soars In Debut, Shares Rebound; KM Birla Lauds Success -
JPMorgan CEO Jamie Dimon Hails PM Modi's Economic Reforms, Urges US to Follow Suit; Details -
Rs. 60/Share Dividend: Record Date On 28 June; Buy The Bajaj Group Stock For 600% Payout? -
Intraday Trade Call: Day Trading Stock Picks By Chandan Taparia Of Motilal Oswal On Thurday, 25 April -
Trade Setup: Nifty Continues Winning Streak Ahead of April F&O Expiry, Q4 Earnings In Focus -
Rs 10/Share Dividend: Record Date In Due Course; Buy The Banking Stock To Be Eligible? -
Stock Market Live Updates: Indian Market Stable In Green; Sensex Trades At 74,095 Levels, Nifty Up 0.28% -
Tech Mahindra Q4 Results Preview: Revenue May Fall, But Margins Seen To Expand; To Announce Dividend -
Rs. 7.75/Share Dividend: Record Date In Due Course; Buy The TATA Group Stock? -
Trade Call: Day Trading Stock Picks By Sumeet Bagadia of Choice Broking On Thursday, 25th April
Venus Remedies rallies on launch of new cancer formulation
Venus Remedies Limited has introduced for the first time a nanotechnology based "Ready to use" Single Vial Docetaxel in the domestic market under the brand name "TAXEDOLA semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.
TAXEDOL (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff.
Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.
GoodReturns.in
